Faron, etusivu

releases and publications

Further re: Exercise of options

Regulatory

BEXMAB Insights into Patient Profiles

Regulatory

Exercise of options

Regulatory

Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial

Regulatory

Faron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Faron’s Financial Calendar for 2024

Regulatory

Phase 1 BEXMAB data presented at ASH

Regulatory

MATINS Trial in Cell Reports Medicine

Grant of options

Insider Transaction Regulatory

Faron Initiates Phase 2 Part of BEXMAB Study

Regulatory
PreviousNext
Back to top